ABCB1 overexpression
|
SCCHN
|
ABCB1 overexpression
|
SCCHN
|
cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials
|
cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials
|
ABCB1 overexpression
|
Head and Neck Cancer
|
ABCB1 overexpression
|
Head and Neck Cancer
|
paclitaxel Resistant: C3 – Early Trials
|
paclitaxel Resistant: C3 – Early Trials
|
ABCB1 overexpression
|
NSCLC
|
ABCB1 overexpression
|
NSCLC
|
paclitaxel Resistant: D – Preclinical
|
paclitaxel Resistant: D – Preclinical
|
ABCB1 overexpression
|
Multiple Myeloma
|
ABCB1 overexpression
|
Multiple Myeloma
|
carfilzomib Resistant: D – Preclinical
|
carfilzomib Resistant: D – Preclinical
|
ABCB1 overexpression
|
CRC
|
ABCB1 overexpression
|
CRC
|
PF-05212384 Resistant: D – Preclinical
|
PF-05212384 Resistant: D – Preclinical
|
ABCB1 overexpression
|
Ovarian Cancer
|
ABCB1 overexpression
|
Ovarian Cancer
|
lapatinib + HM 78136B Sensitive: D – Preclinical
|
lapatinib + HM 78136B Sensitive: D – Preclinical
|